Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.

about

Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.

Item

http://www.wikidata.org/entity/Q41686238

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Contribution of rivaroxaban to ...... ermined by simulation studies.

@en

type

Item

label

Contribution of rivaroxaban to ...... ermined by simulation studies.

@en

prefLabel

Contribution of rivaroxaban to ...... ermined by simulation studies.

@en

P1476

Contribution of rivaroxaban to ...... ermined by simulation studies.

@en

P2093

Dagmar Kubitza

http://www.w3.org/2001/XMLSchema#string

Hans-Ulrich Siegmund

http://www.w3.org/2001/XMLSchema#string

Katrin Coboeken

http://www.w3.org/2001/XMLSchema#string

Rolf Burghaus

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.

Assays for measuring rivaroxaban: their suitability and limitations.

How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

P304

959-966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12571

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25510952

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

P932

4456128

http://www.w3.org/2001/XMLSchema#string